JP2017522270A - 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン - Google Patents

全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン Download PDF

Info

Publication number
JP2017522270A
JP2017522270A JP2016568653A JP2016568653A JP2017522270A JP 2017522270 A JP2017522270 A JP 2017522270A JP 2016568653 A JP2016568653 A JP 2016568653A JP 2016568653 A JP2016568653 A JP 2016568653A JP 2017522270 A JP2017522270 A JP 2017522270A
Authority
JP
Japan
Prior art keywords
compound
biomarker
sle
level
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522270A5 (enExample
Inventor
エイチ．シャフェル ピーター
エイチ．シャフェル ピーター
ウウ レイ
ウウ レイ
イエ イイング
イエ イイング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2017522270A publication Critical patent/JP2017522270A/ja
Publication of JP2017522270A5 publication Critical patent/JP2017522270A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2016568653A 2014-05-19 2015-05-18 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン Pending JP2017522270A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462000428P 2014-05-19 2014-05-19
US62/000,428 2014-05-19
US201462053626P 2014-09-22 2014-09-22
US62/053,626 2014-09-22
PCT/US2015/031345 WO2015179276A1 (en) 2014-05-19 2015-05-18 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080644A Division JP2020143083A (ja) 2014-05-19 2020-04-30 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン

Publications (2)

Publication Number Publication Date
JP2017522270A true JP2017522270A (ja) 2017-08-10
JP2017522270A5 JP2017522270A5 (enExample) 2018-06-28

Family

ID=53268937

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016568653A Pending JP2017522270A (ja) 2014-05-19 2015-05-18 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン
JP2020080644A Pending JP2020143083A (ja) 2014-05-19 2020-04-30 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン
JP2021213603A Pending JP2022058443A (ja) 2014-05-19 2021-12-28 全身性エリテマトーデスの治療のための３－（４－（（４－（モルホリノメチル－ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020080644A Pending JP2020143083A (ja) 2014-05-19 2020-04-30 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン
JP2021213603A Pending JP2022058443A (ja) 2014-05-19 2021-12-28 全身性エリテマトーデスの治療のための３－（４－（（４－（モルホリノメチル－ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン

Country Status (6)

Country Link
US (5) US10245266B2 (enExample)
EP (1) EP3145513B1 (enExample)
JP (3) JP2017522270A (enExample)
ES (1) ES2969532T3 (enExample)
TW (2) TWI745271B (enExample)
WO (1) WO2015179276A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143083A (ja) * 2014-05-19 2020-09-10 セルジーン コーポレイション 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン
JP2023544351A (ja) * 2020-10-02 2023-10-23 セルジーン コーポレーション 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201501062SA (en) 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CN114939119A (zh) 2012-08-09 2022-08-26 细胞基因公司 免疫相关和炎性疾病的治疗
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
KR20210069642A (ko) 2018-10-01 2021-06-11 셀진 코포레이션 암 치료를 위한 병용 요법
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
WO2014025958A2 (en) * 2012-08-09 2014-02-13 Celgene Corporation Treatment of immune-related and inflammatory diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
TR200101504T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı.
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
GB0120441D0 (en) 2001-08-22 2001-10-17 Novartis Forschungsstiftung Model of autoimmune disease and methods for identifying anti autoimmune disease disorders
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US8088591B2 (en) 2006-05-12 2012-01-03 University Of Miami Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma
US20080045485A1 (en) 2006-08-17 2008-02-21 Peter Muir Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
MX2009010082A (es) 2007-03-20 2009-10-19 Celgene Corp Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma.
CN101680887B (zh) 2007-03-30 2014-06-25 褚圣-贾斯汀公司 测定脊柱侧凸风险的方法
JP5442185B2 (ja) 2007-04-24 2014-03-12 日本メナード化粧品株式会社 感作性物質評価方法
CA2720184C (en) 2008-03-31 2017-07-18 Boston Medical Center Corporation Predictive marker for topoisomerase i inhibitors
CA2723648A1 (en) 2008-04-10 2009-10-15 Piyush Gupta Methods for identification and use of agents targeting cancer stem cells
CA2744711C (en) 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BRPI1011394A8 (pt) 2009-04-18 2018-06-26 Genentech Inc método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40
SG10201501062SA (en) 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
MX2012010367A (es) * 2010-03-12 2012-11-23 Celgene Corp Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
CA2808417A1 (en) 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
AU2012220872A1 (en) 2011-02-22 2013-09-12 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers
US9730941B2 (en) * 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
US9371568B2 (en) * 2012-07-31 2016-06-21 Novartis Ag Markers associated with human double minute 2 inhibitors
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
JP2017522270A (ja) * 2014-05-19 2017-08-10 セルジーン コーポレイション 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
WO2014025958A2 (en) * 2012-08-09 2014-02-13 Celgene Corporation Treatment of immune-related and inflammatory diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143083A (ja) * 2014-05-19 2020-09-10 セルジーン コーポレイション 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン
JP2023544351A (ja) * 2020-10-02 2023-10-23 セルジーン コーポレーション 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用

Also Published As

Publication number Publication date
US20170173029A1 (en) 2017-06-22
JP2022058443A (ja) 2022-04-12
US20200360396A1 (en) 2020-11-19
US11660302B2 (en) 2023-05-30
US20220008427A1 (en) 2022-01-13
ES2969532T3 (es) 2024-05-21
WO2015179276A1 (en) 2015-11-26
TWI745271B (zh) 2021-11-11
EP3145513A1 (en) 2017-03-29
TW201622728A (zh) 2016-07-01
TWI794885B (zh) 2023-03-01
US10596179B2 (en) 2020-03-24
EP3145513B1 (en) 2023-11-15
US20190262348A1 (en) 2019-08-29
US10980812B2 (en) 2021-04-20
US20240041894A1 (en) 2024-02-08
JP2020143083A (ja) 2020-09-10
TW202216156A (zh) 2022-05-01
US10245266B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
US11660302B2 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
US20140343058A1 (en) Treatment of systemic lupus erythematosus
JP2016188214A (ja) グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
MX2015004563A (es) Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
EP2753931A1 (en) Autoimmune and inflammatory disorder therapy
KR20220011652A (ko) 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법
KR20220163986A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
WO2024223740A1 (en) Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
US20160067272A1 (en) Methods for treating immune diseases
EP3376869B1 (en) Treatment of autoimmune disease
SUgITA et al. Drug-induced papuloerythroderma: analysis of T-cell populations and a literature review
US20230091561A1 (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
BR112017020591B1 (pt) Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2- trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
TWI899163B (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200430

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200519

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200617

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200612

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200710

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200714

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210802

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211118

C27C Written answer of applicant after an oral proceeding

Free format text: JAPANESE INTERMEDIATE CODE: C2721

Effective date: 20220222

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220329

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20220330

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220510

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220510